REVB · Revelation Biosciences, Inc. · Executive Compensation
$3.71
+0.02 (+0.54%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for September 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$2.52M
Shares
683,442
Volume · Nov 20
1858
Avg daily vol (23 sessions)
20.32K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Chester S. Zygmont, III | Chief Financial Officer | Appointed | 2026-06-24 |
| James Rolke | Chief Executive Officer | Appointed | 2026-06-24 |
| Jennifer Carver | Class A director |
Already on the board
Since at least 2020: re-election or new board role
|
2026-06-24 |
|
George Tidmarsh, M.D., Ph.D.
“The resignation of Dr. Tidmarsh was not a result of any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Class C Director | Resigned | 2025-05-28 |
| Lakhmir Chawla M.D. | Class C Director | Appointed | 2023-10-02 |
|
Curt LaBelle, M.D.
“The resignation of Dr. LaBelle was not a result of any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2023-10-02 |
| Andreas Typaldos | executive officer | Resigned | 2022-01-14 |
| Sean Fitzpatrick | executive officer | Resigned | 2022-01-14 |
| Barry Dennis | director | Resigned | 2022-01-14 |
| William Carson | director | Resigned | 2022-01-14 |
| Anthony Hayes | director | Resigned | 2022-01-14 |
| Robert Nicholson | director | Resigned | 2022-01-14 |
| Andreas Typaldos | director | Resigned | 2022-01-14 |
| David Dobkin | director | Resigned | 2022-01-14 |
| Curt LaBelle | director | Appointed | 2022-01-14 |
| Jess Roper | director | Appointed | 2022-01-14 |
| Jennifer Carver | director | Appointed | 2022-01-14 |
| James Rolke | director | Appointed | 2022-01-14 |
| George F. Tidmarsh | director | Appointed | 2022-01-14 |
Leadership
- James Rolke CEO, Board Member
- Chester S. Zygmont CFO
- Chester S. Zygmont, III CFO
- Curt LaBelle Board Member
- George F. Tidmarsh Board Member
- Jennifer Carver Board Member
- Jess Roper Board Member
- Lakhmir Chawla Board Member
- Lakhmir Chawla M.D. Board Member
- William H. Carson Board Member
Key facts
CIK
1810560
CUSIP
76135L887
13F (30d)
16 filings
14 filers
Visit website
Investor relations